Cookies on the BTG website

We use cookies to ensure that we give you the best experience on our website.

If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the BTG website.

Find out more
Continue

Investors

Utilities
Print
Email
Email to a friend
Email to a friend

* Required

Analyst Coverage

Research analysts have, from time to time, published material commenting on BTG. Any opinions, estimates or forecasts regarding the Company's performance made by such analysts are theirs alone and do not represent opinions, forecasts or predictions of the Company or its Management. You should, therefore, not place undue reliance on the content of any such analyst report or statement. The following analysts currently issue reports on us:

 
CompanyAnalyst
Deutsche BankRichard Parkes
Edison Investment ResearchRobin Davison
FinnCapKeith Redpath
InvestecNicholas Keher
J.P. Morgan CazenoveJames Gordon
JefferiesPeter Welford
N+1SingerElizabeth Klein
New Street ResearchChris Donnellan
NumisCharles Weston
Panmure GordonSavvas Neophytou
Peel HuntPaul Cuddon
Shore CapitalBrian White

These reports cannot be obtained directly from us. Any reports issued may have become out of date following publication and should be read accordingly.

Retaining value

We regained US sales and marketing rights for some of our specialty pharmaceuticals and interventional medicines and now sell these products direct through our specialist sales teams, enabling us to benefit from 100% of the sales revenues.

Investor contacts
Contacts

We have a variety of different investor and shareholder contacts depending on the nature of your enquiry.